Supriya Lifescience Limited share price
NSE: SUPRIYA · ISIN INE07RO01027
Key numbers
- Market cap
- ₹ 7,929 Cr
- Current price
- ₹ 985.20
- 52-week high / low
- ₹ 1,085 / 546
- Stock P/E
- 40.0
- Book value
- ₹ 148.8
- Dividend yield
- 0.10%
- ROCE
- 25.0%
- ROE
- 19.1%
- Debt to equity
- 0.00
- Sales growth (3 yrs)
- 21.2%
- Profit growth (3 yrs)
- 32.5%
- 1-year return
- 33.4%
About Supriya Lifescience Limited
Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, antihypertensive, vitamins, anti-malarial, and anti-gout areas. It also provides oncology, veterinary, and general category products. In addition, the company offers GelHeal, a wound care solution; and Quickblue, an oral cancer detection kit. Further, it is developing drugs in the areas of anti-depressant, anti-inflammatory, contrast media, hormones, antibiotic, smoking cessation, anti-diabetic/obesity, anti-ataxia, decongestant, veterinary API, anti-cancer, allogeneic hematopoietic stem cell transplantation, and anti-migraine. Supriya Lifescience Limited was founded in 1987 and is headquartered in Mumbai, India.
Quarterly results
Consolidated figures in ₹ crores
| Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 145 | 200 | 206 | 277 | 190 |
| Operating profit | 52 | 73 | 72 | 98 | 47 |
| Net profit | 35 | 50 | 50 | 74 | 24 |
| EPS (₹) | 4.32 | 6.27 | 6.17 | 9.22 | 2.99 |
Concall summary (2026-08-18)
AI summary of the earnings call transcript · tone: Positive · source document
Guidance & outlook
- We remain confident of our guidance of EBITDA margins in the range of 33% to 35%.
- Importantly, these are largely transient in nature, and we remain confident of delivering our FY27 growth and margin guidance.
Growth & demand
- Exports continued to be a key growth driver contributing 81% of revenue in Q1 FY '27.
- Now, coming to our new product launches: We launched two new anesthetic liquid inhalation products in Q2 FY '27 from our Ambernath facility and we expect them to scale up over the coming quarters.
Margins & costs
- 52 crores in Q1 FY '26, a degrowth of 8.1% year-on-year and EBITDA margin stood at 25% for Q1 FY '27.
- As mentioned by our Joint Managing Director, margins during the quarter were impacted by temporary cost headwinds, primarily higher solvent and power costs.
Capex & expansion
- 16.58 crores driven by spend on maintenance CapEx, smaller projects, formulation plan requirements and Isambe project.
- Say, right from the acquisition, around 2.5 years, we should have a 40% completion as per MIDC.
Balance sheet & cash
- On borrowings, we would like to report that for the full year, we have not utilized any working capital limits, except for letter of credits and bank guarantees.
Peers in Biotechnology
Data for information only, not investment advice. Prices end of day.